Abstract

Extracellular Vesicles: Paving the Way to Automation and Standardization in Precise Isolation and Single-particle Characterization

Stephane Mazlan, Scientific and Business Coordinator, Izon Science

Reproducible, efficient isolation is the foundation of all aspects of extracellular vesicle (EV) research and development, including the discovery, validation, and implementation of EV-based biomarkers. Izon Science has led the way in developing and producing products and services aimed at EV isolation for diagnostic purposes. With our qEV Gen 2 columns we have pushed isolate purity further than ever before, improving protein depletion in the EV-enriched volumes for both our 35 nm (98.8 ± 0.03 % depletion; 1.6-fold improvement on Legacy; p<0.05) and 70 nm (99.5 ± 0.09 % depletion; 1.4-fold improvement on Legacy; p<0.05) Series columns. Both Gen 2 series also see improved depletion of LDL and HDL as quantified using an ELISA for ApoB and ApoA1 respectively (p<0.05 for Gen 2 vs Legacy). These improved columns are already helping customers to improve their EV isolation for diagnostics. Stephane Mazlan (PhD), Izon’s Regional Business Director (EMEA), will discuss our new service, qEV PurePath for Diagnostics. This customizable service, and the new instrumentation developed as part of this diagnostics-focused project, will substantially improve the development and throughput of EV isolation for diagnostics, aiding your journey to commercialization.?Dr Mazlan will provide an update on Izon’s?product pipeline, including new members of the qEV family which are focused on isolating new subsets of particles and further improving EV isolate purity.?Most importantly, at Izon Science we use our experience in EV isolation optimization to work with you, helping you to bring your EV-based diagnostic to market.